Transcat, Inc. Prices $70 Million Public Offering of Common Stock

Stock Information for BioXcel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioXcel Therapeutics Inc.

Transcat Inc. Announces Executive Leadership Changes
Transcat Reports Strong Third Quarter Results on Service Gross Margin Expansion and Adjusted EBITDA Growth
Transcat Announces Third Quarter Fiscal Year 2024 Conference Call and Webcast
Transcat Reports Strong Second Quarter Results on Double-Digit Organic Service Growth and Expanding Gross Margins
Transcat Announces Second Quarter Fiscal Year 2024 Conference Call and Webcast
Transcat, Inc. Announces Proposed Public Offering of Common Stock
Transcat accelerates the growth of its high margin rental business with the acquisition of Axiom Test Equipment, Inc.
Transcat Reports Strong First Quarter Results on Double-Digit Organic Service Growth and Expanding Gross Margins

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.